title: [Biotechnological advances in monoclonal antibody therapy: the RANK ligand inhibitor antibody].
abstract: Biological drugs have been used since the middle of the last century in medicine. Nowadays we are witnesses of the intensive development and wider administration of these drugs in clinical practice. Around 250 biological drugs are available and more than 350 million patients have been treated since their marketed authorization. Among the biologics there are protein based macromolecules, which mass production can be performed with the help of biotechnology. This term referring to the use of living organisms for production of molecules, was introduced by the Hungarian engineer, Károly Ereky. The present review focuses on the research, production and development of monoclonal antibodies manufactured by biotechnology. Some steps of this development have changed our immunological knowledge and the outcome of several diseases. The development of antibodies was highly recognized by two Nobel prizes. Authors detail the structure and functions of immunoglobulins, and their development, including fully human monoclonal antibodies. The RANKL inhibitor denosumab, a fully human IgG2 monoclonal antibody belongs to this latter group and it is available for treatment of osteoporosis. Authors also summarize the basic process of bone metabolism and the benefits of RANK ligand inhibition.
authors.affiliation: Semmelweis Egyetem, Általános Orvostudományi Kar III, Belgyógyászati Klinika Reumatológiai és Fizioterápiás Tanszéki Csoport II, Kihelyezett Részleg, Frankel Leó út 38-40, Budapest. drkissemese@freemail.hu
authors.forename: Emese
authors.initials: E
authors.lastname: Kiss
authors.forename: Zénó
authors.initials: Z
authors.lastname: Kuluncsics
authors.forename: Zoltán
authors.initials: Z
authors.lastname: Kiss
authors.forename: Gyula
authors.initials: G
authors.lastname: Poór
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001709:Biotechnology / Q000639:trends*; D000069448:Denosumab; D006801:Humans; D007074:Immunoglobulin G / Q000378:metabolism; D009613:Nobel Prize; D010024:Osteoporosis / Q000188:drug therapy; D053245:RANK Ligand / Q000276:immunology / Q000378:metabolism* / Q000494:pharmacology
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D053245:RANK Ligand; D000069448:Denosumab